Dicerna Pharmaceuticals, Inc. (DRNA) At $13.08 Forms Top; Daruma Capital Management Has Cut By $652,800 Its Microsemi (MSCC) Stake

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Logo

Daruma Capital Management Llc decreased Microsemi Corp (MSCC) stake by 13.26% reported in 2018Q1 SEC filing. Daruma Capital Management Llc sold 10,200 shares as Microsemi Corp (MSCC)’s stock rose 7.00%. The Daruma Capital Management Llc holds 66,746 shares with $4.32 million value, down from 76,946 last quarter. Microsemi Corp now has $8.11B valuation. The stock increased 0.01% or $0.01 during the last trading session, reaching $68.74. About 4.80M shares traded or 72.19% up from the average. Microsemi Corporation (NASDAQ:MSCC) has risen 37.87% since June 22, 2017 and is uptrending. It has outperformed by 25.30% the S&P500. Some Historical MSCC News: 23/05/2018 – Microsemi Wins “Outstanding Components Vendor” Award from Light Reading; 24/04/2018 – Microsemi Delivers First Validation of a Single-root Input/Output NVMe SSD with an Advanced Fabric PCIe Switch for Virtualizati; 29/05/2018 – News On Microsemi Corp. (MSCC) Now Under MCHP; 26/04/2018 – Microsemi Expands Switchtec Family of PCle Switches to Support Extended Industrial Temperature Range; 07/05/2018 – MICROCHIP TECHNOLOGY ON REPORTS OF MOFCOM APPROVAL FOR MICROSEMI DEAL – “CANNOT CONFIRM TODAY’S REPORT IN THE PRESS THAT CHINA’S MOFCOM HAS CLEARED” DEAL; 14/05/2018 – Water Island Capital Buys New 1.1% Position in Microsemi; 20/04/2018 – NXP SEMI GAINS PRE-MKT AS MSCC/MCHP UNDER MOFCOM SIMPLE REVIEW; 15/05/2018 – MICROCHIP TECHNOLOGY – ANTICIPATES THAT MICROSEMI MERGER WILL BE COMPLETED IN LATE MAY/EARLY JUNE; 15/05/2018 – Microchip gets China antitrust approval to buy Microsemi; 20/03/2018 – BlackRock Science & Tech Adds Microsemi, Exits Qualcomm

Dicerna Pharmaceuticals, Inc. (DRNA) formed multiple top with $13.73 target or 5.00% above today’s $13.08 share price. Dicerna Pharmaceuticals, Inc. (DRNA) has $690.91 million valuation. The stock increased 3.81% or $0.48 during the last trading session, reaching $13.08. About 670,567 shares traded or 18.21% up from the average. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has risen 317.27% since June 22, 2017 and is uptrending. It has outperformed by 304.70% the S&P500. Some Historical DRNA News: 20/04/2018 – Alnylam: Dicerna to Be Restricted in Its Development of Certain Therapeutics for 18 Mos to Four Years; 20/04/2018 – Alnylam Reaches Settlement Agreement with Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation and Other Pending; 14/05/2018 – Dicerna Pharmaceuticals Believes It Has Sufficient Cash Through 2019, Assuming No New Fundin; 08/03/2018 – DICERNA SEES SUFFICIENT CASH TO FUND DEVELOPMENT THRU 2019; 08/03/2018 – DICERNA PHARMACEUTICALS – BELIEVES IT HAS SUFFICIENT CASH TO FUND EXECUTION OF CURRENT CLINICAL AND OPERATING PLAN THROUGH 2019; 17/05/2018 – Dicerna Treatment Granted Orphan Drug Status by FDA; 19/04/2018 – DJ Dicerna Pharmaceuticals Inc, Inst Holders, 1Q 2018 (DRNA); 09/04/2018 – Dicerna Presenting at Conference Tomorrow; 14/05/2018 – Dicerna Pharmaceuticals 1Q Loss/Shr 30c; 17/04/2018 – STAT Plus: Trade secrets battle between Alnylam, Dicerna is just one of many

Investors sentiment decreased to 2.44 in 2018 Q1. Its down 0.56, from 3 in 2017Q4. It turned negative, as 3 investors sold Dicerna Pharmaceuticals, Inc. shares while 13 reduced holdings. 24 funds opened positions while 15 raised stakes. 30.68 million shares or 5.45% more from 29.10 million shares in 2017Q4 were reported. Manchester Cap Limited Liability Company accumulated 18,857 shares or 0.03% of the stock. 1.71M were accumulated by Fmr Limited Liability Com. Geode Capital Mgmt Ltd Liability reported 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Jane Street Group Ltd, a New York-based fund reported 14,262 shares. Bogle Invest Management Ltd Partnership De invested in 0.01% or 18,798 shares. Morgan Stanley owns 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 14,362 shares. Quantitative Systematic Strategies Llc has 11,794 shares. Cubist Systematic Strategies has invested 0.01% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Element Management Limited Company has invested 0.02% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Manufacturers Life Insurance Company The reported 1,825 shares. Birchview Cap Limited Partnership holds 0.28% or 45,000 shares. Panagora Asset Mgmt, a Massachusetts-based fund reported 7,533 shares. Barclays Plc owns 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 41,590 shares. Bluecrest Capital Ltd, Guernsey-based fund reported 114,650 shares. Moreover, Eam Investors Limited Liability Co has 0.08% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA).

Analysts await Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) to report earnings on August, 9. They expect $-0.42 earnings per share, up 63.48% or $0.73 from last year’s $-1.15 per share. After $-0.30 actual earnings per share reported by Dicerna Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 40.00% negative EPS growth.

Since March 19, 2018, it had 0 buys, and 4 selling transactions for $425,035 activity. Brown Bob D also sold $145,035 worth of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shares. $116,545 worth of stock was sold by Weissman James B on Friday, April 20.

Among 9 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 4 have Buy rating, 0 Sell and 5 Hold. Therefore 44% are positive. Dicerna Pharmaceuticals had 25 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, August 11 by H.C. Wainwright. FBR Capital initiated Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) on Tuesday, March 27 with “Hold” rating. The firm has “Buy” rating given on Wednesday, November 11 by Stifel Nicolaus. The company was maintained on Friday, March 9 by Stifel Nicolaus. The company was maintained on Tuesday, May 10 by Stifel Nicolaus. The stock has “Buy” rating by Stifel Nicolaus on Monday, August 10. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Mkt Perform” rating by Leerink Swann on Tuesday, January 31. The rating was downgraded by H.C. Wainwright to “Neutral” on Friday, March 23. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, November 2. The stock has “Hold” rating by Chardan Capital Markets on Friday, March 9.

More news for Microsemi Corporation (NASDAQ:MSCC) were recently published by: Streetinsider.com, which released: “Microchip Technology (MCHP) Completes Acquisition of Microsemi (MSCC)” on May 29, 2018. Seekingalpha.com‘s article titled: “PRAH +3% on MidCap 400 move; ABMD to S&P 500” and published on May 25, 2018 is yet another important article.

Since March 8, 2018, it had 0 insider purchases, and 4 sales for $821,093 activity. $243,405 worth of Microsemi Corporation (NASDAQ:MSCC) was sold by FOLINO PAUL F on Thursday, May 10. 2,090 shares were sold by Goren David, worth $138,841. $136,130 worth of Microsemi Corporation (NASDAQ:MSCC) was sold by Goerner Frederick C.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) Institutional Positions Chart